STOCKS PARE LOSSES, S&P 500 SET FOR WORST H1 IN 52 YEARS

U.S. consumer spending cools in sign of economy on weaker footing amid soaring inflation

Janux Therapeutics, Inc. (JANX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

12.18

+0.74

(+6.47%)

As of 03:03PM EDT. Market open.

Loading interactive chart...

Business Wire
Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference
SAN DIEGO, June 02, 2022--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at the 2022 Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 11:00 a.m. ET in New York, New York.
Business Wire
Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, May 31, 2022--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s investigational new drug (IND) application for its lead product candidate, JANX007, a PSMA-TRACTr in development
Simply Wall St.
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. For example, although...